Delphinus Medical Technologies, a Novi, MI-based dense breast medical imaging provider, raised $12M in Growth funding.
Trinity Capital (NASDAQ: TRIN) provided the financial resources.
The company intends to use the funds to continue to scale operations, broadening its impact on the global healthcare community.
Led by Mark J. Forchette, President and CEO, Delphinus Medical Technologies is a medical imaging company that has developed SoftVue™, featuring a circular array transducer technology. The patented technology is a 3D whole breast ultrasound tomography system that delivers no radiation, requires no compression, and images the entire breast with a single scan.
RELATED: Louisiana Healthcare Startup Secures $1M in Funding
SoftVue™ has previously received three 510(k)s, and the PMA approval for dense breast screening adjunct to mammography expands the company’s existing platform of approvals to include breast cancer screening in asymptomatic women with dense breast parenchyma after confirmation that the breast density composition is BI-RADS c or d at the time of screening mammography. It can be used at the same visit as screening mammography, and the SoftVue™ images are intended to be interpreted with the mammogram results to enhance screening.
